logo
logo
VRTX stock ticker logo

Vertex Pharmaceuticals Incorporated

NASDAQ•VRTX
CEO: Dr. Jeffrey Marc Leiden M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1991-07-24
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Contact Information
50 Northern Avenue, Boston, MA, 02210, United States
617-341-6100
www.vrtx.com
Market Cap
$126.79B
P/E (TTM)
32.1
17.5
Dividend Yield
--
52W High
$519.68
52W Low
$362.50
52W Range
87%
Rank29Top 17.8%
5.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$3.23B+0.00%
4-Quarter Trend

EPS

$4.69+0.00%
4-Quarter Trend

FCF

$348.60M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Growth Total revenues reached $12.0B USD in 2025, marking a 9% increase from $11.0B USD reported in 2024.
Profitability Rebound Switched to Net Income of $3.95B USD in 2025, recovering from $535.6M net loss reported in the prior year.
Strong Cash Position Cash, equivalents, and securities grew 10% to $12.3B USD by year-end 2025, supporting operations and investment.
New Product Revenue CASGEVY generated $115.8M USD revenue in 2025; JOURNAVX contributed $59.6M USD following its March 2025 launch.

Risk Factors

CF Revenue Concentration Risk Business substantially dependent on CF medicines; revenue concentration increases risk from competitive products or supply disruptions.
R&D Pipeline Execution Risk Pipeline advancement uncertain; recorded $379.0M impairment charge for discontinued VX-264 T1D program in Q1 2025.
Pricing and Reimbursement Pressures Subject to pricing controls globally; payor decisions restricting coverage could limit market acceptance and revenue growth.
Intellectual Property Disputes Facing confidential arbitration regarding ALYFTREK royalty burden; IP protection remains complex and subject to challenges.

Outlook

Pivotal Pipeline Advancement Advancing povetacicept for IgAN; expect Phase 3 interim data in H1 2026; inaxaplin interim analysis late 2026 or early 2027.
CASGEVY Pediatric Expansion Expect global regulatory submissions for CASGEVY in children 5 to 11 years old in the first half of 2026.
Continued Innovation Investment Plan to continue investing in serial innovation strategy, advancing diverse pipeline, and expanding manufacturing capabilities.
JOURNAVX Commercial Growth Expect SG&A expenses to increase in 2026 supporting JOURNAVX expansion and anticipated povetacicept launch.

Peer Comparison

Revenue (TTM)

CVS stock ticker logoCVS
$402.07B
+7.8%
MCK stock ticker logoMCK
$397.96B
+15.5%
HCA stock ticker logoHCA
$75.60B
+7.1%

Gross Margin (Latest Quarter)

ARGX stock ticker logoARGX
89.3%
-53.8pp
VRTX stock ticker logoVRTX
85.6%
+0.7pp
REGN stock ticker logoREGN
85.0%
+3.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SYK$137.25B42.315.0%31.1%
VRTX$126.79B32.122.7%14.9%
BMY$122.45B17.439.3%52.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.2%
Steady Growth
4Q Net Income CAGR
22.6%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 4, 2026
|
EPS:$4.42
|
Revenue:$3.05B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data